Robotic magnetic navigation

Heart Centre Rigshospitalet Copenhagen Celebrates 5,000 Robotic Cardiac Ablation Procedures

Retrieved on: 
Wednesday, May 4, 2022
Arrhythmia, U.S. Securities and Exchange Commission, Forward-looking statement, University, Copenhagen University Hospital, Electrophysiology, IT University of Copenhagen, Health, GLOBE, Company, NYSE, Stroke, Heart failure, Safety, Physician, Robotics, Patient, Security (finance), Disaster, Shahid Gangalal National Heart Centre, Hospital, Copenhagen, Robotic magnetic navigation, Arrest, Pandemic, Intelligence, CEO, Technology, Heart, Cardiology, Rigshospitalet, Ventricular septal defect, Risk, Medical device, Stereotaxis

ST. LOUIS, May 04, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, celebrates the achievements of the highly skilled electrophysiology team at The Heart Centre Rigshospitalet , Copenhagen University Hospital for successfully completing more than 5,000 robotic cardiac ablation procedures using Denmarks only robotic system for the treatment of heart rhythm disorders.

Key Points: 
  • ST. LOUIS, May 04, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, celebrates the achievements of the highly skilled electrophysiology team at The Heart Centre Rigshospitalet , Copenhagen University Hospital for successfully completing more than 5,000 robotic cardiac ablation procedures using Denmarks only robotic system for the treatment of heart rhythm disorders.
  • The Heart Centre Rigshospitalet at the University of Copenhagen is the leading user of advanced robotic technology for the treatment of cardiac arrhythmias among a hundred hospitals globally.
  • Electrophysiologists use the technology to repair the electrical circuits of the heart in a minimally invasive procedure called cardiac ablation.
  • Clinical cardiac electrophysiologist, Dr. Xu Chen, leads physicians in the world with the most robotic cardiac ablation procedures performed with Stereotaxis technology, having completed over 4,000 procedures.

National Institute of Cardiology Becomes First Hospital in Poland to Establish Advanced Robotic Program to Treat Heart Rhythm Disorders

Retrieved on: 
Thursday, March 24, 2022
Arrest, Company, Risk, Pandemic, Robotic magnetic navigation, Forward-looking statement, Arrhythmia, Electrophysiology, NYSE, Genesis, Disaster, Hospital, Ageing, National Institute, CEO, U.S. Securities and Exchange Commission, Prevalence, Intelligence, Health, Technology, Safety, Stroke, RMN, GLOBE, Physician, Heart failure, Patient, Security (finance), Medical device, Cardiology, Stereotaxis

The National Institute of Cardiology is the only hospital in Poland offering advanced robotic technology to improve the minimally invasive treatment of heart arrhythmias.

Key Points: 
  • The National Institute of Cardiology is the only hospital in Poland offering advanced robotic technology to improve the minimally invasive treatment of heart arrhythmias.
  • The Genesis RMN system introduces the benefits of robotic precision and safety to cardiac ablation, a common, minimally invasive procedure to treat arrhythmias.
  • We are proud that we can bring this new and innovative robotic technology to Poland, says Leszek Pitek, Vice President of Consultronix, distributor of advanced medical equipment in Poland.
  • We are delighted to partner with the National Institute of Cardiology and Consultronix to pioneer the benefits of Robotic Magnetic Navigation in Poland, said David Fischel, Chairman and CEO of Stereotaxis.

Stereotaxis Announces Grand Opening of New Global Headquarters in St. Louis

Retrieved on: 
Wednesday, March 9, 2022
Safety, Globe Building, Physician, Disaster, Company, U.S. Securities and Exchange Commission, Robotic magnetic navigation, Golden Joystick Awards, Health, Entrepreneurship, News, Hospital, NYSE, GLOBE, Patient, Security (finance), Technology, Pandemic, Growth, Intelligence, CEO, Forward-looking statement, St. Louis Board of Aldermen, Stereotaxis

ST. LOUIS, March 09, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today is holding the grand opening of its new, 45,000-square-foot global headquarters facility in downtown St. Louis.

Key Points: 
  • ST. LOUIS, March 09, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today is holding the grand opening of its new, 45,000-square-foot global headquarters facility in downtown St. Louis.
  • Stereotaxis, which employs over 130 professionals in ten countries globally, designed its headquarters to accommodate significant long-term growth.
  • David Fischel and Governor Parson will demonstrate Stereotaxis robotic surgical technology in one of the headquarters interventional operating rooms in which doctors are trained on the equipment.
  • Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention.

Fuwai Central China Cardiovascular Hospital Becomes First to Offer Advanced Robotic Treatment for Heart Rhythm Disorders in Central China

Retrieved on: 
Thursday, January 27, 2022
U.S. Securities and Exchange Commission, CEO, Health, Robotic magnetic navigation, Physician, Intelligence, Forward-looking statement, Heart, Arrhythmia, Risk, Electrophysiology, Disaster, Pandemic, Arrest, Heart failure, Technology, Stroke, Leadership, Security (finance), Company, Patient, Hospital, NYSE, GLOBE, Safety, Medical device, Stereotaxis

Robotic Magnetic Navigation is the most advanced electrophysiology assisted catheter operating system in the world.

Key Points: 
  • Robotic Magnetic Navigation is the most advanced electrophysiology assisted catheter operating system in the world.
  • Tens of millions of individuals worldwide suffer from arrhythmias abnormal heart rhythms that result when the heart beats too quickly, too slowly, or with an irregular pattern.
  • Robotic Magnetic Navigation introduces the benefits of robotic precision and safety to cardiac ablation, a common, minimally invasive procedure to treat arrhythmias.
  • We are delighted by the success of Fuwai Central China Cardiovascular Hospital, said David Fischel, chairman and CEO of Stereotaxis.

HonorHealth Scottsdale Shea Medical Center Builds Advanced Robotic Program to Treat Heart Rhythm Disorders

Retrieved on: 
Tuesday, January 25, 2022
U.S. Securities and Exchange Commission, CEO, Health, Robotic magnetic navigation, Physician, Intelligence, Forward-looking statement, Arrhythmia, Risk, Disaster, Pandemic, Arrest, Heart failure, Technology, Stroke, Leadership, Robotics, Security (finance), Company, Patient, NYSE, GLOBE, RMN, Safety, Medical device, Stereotaxis

ST. LOUIS, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces that HonorHealth has established a robotic electrophysiology program as part of its Cardiovascular Center of Excellence at HonorHealth Scottsdale Shea Medical Center in Scottsdale, Arizona.

Key Points: 
  • ST. LOUIS, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces that HonorHealth has established a robotic electrophysiology program as part of its Cardiovascular Center of Excellence at HonorHealth Scottsdale Shea Medical Center in Scottsdale, Arizona.
  • HonorHealth is among the first in the nation to offer the Genesis Robotic Magnetic Navigation (RMN) system to patients receiving minimally invasive cardiac ablation procedures.
  • Robotic Magnetic Navigation introduces the benefits of robotic precision and safety to cardiac ablation, a common, minimally invasive procedure to treat arrhythmias.
  • We applaud their leadership and look forward to supporting their efforts to improve patient care, advance clinical science, and build a preeminent heart rhythm program.

Stereotaxis Robotic Technology Reduces Incidence of Silent Cerebral Embolism During Atrial Fibrillation Ablation in New Peer-Reviewed Publication

Retrieved on: 
Wednesday, December 8, 2021
Incidence, NYSE, AF, SCE, Embolism, GLOBE, Patient, Technology, Lists of Palestinian rocket attacks on Israel, Robotic magnetic navigation, Frontiers Media, RMN, Arrhythmia, Atrial fibrillation, Medical device, Medical imaging

All patients received cerebral magnetic resonance imaging within 48 hours before and after the ablation procedure to assess cerebral embolism.

Key Points: 
  • All patients received cerebral magnetic resonance imaging within 48 hours before and after the ablation procedure to assess cerebral embolism.
  • Patients treated using RMN had greater than 82% reduced incidence of silent cerebral embolism (SCE) at 5.77% compared to 32.26% in patients treated with manual catheter ablation (p
  • The study concluded, ablation technology is the only independent risk factor of SCEs, and RMN can significantly reduce the incidence of SCEs resulting from AF ablation.
  • Stereotaxis Robotic Magnetic Navigation technology introduces the benefits of robotic precision and safety to cardiac ablation, a common, minimally invasive procedure to treat arrhythmias.

BJC HealthCare Becomes First Health Care System in Midwest to Adopt Latest Robotic Technology for Arrhythmia Treatment

Retrieved on: 
Monday, November 15, 2021
Health, Safety, Robotics, BJC HealthCare, RMN, Pandemic, Radiation, Heart, Arrhythmia, Hospital, CEO, Technology, Arrest, Instagram, Stroke, Forward-looking statement, Robotic magnetic navigation, Electrophysiology, YouTube, Twitter, Company, GLOBE, Awareness, Heart failure, LinkedIn, U.S. Securities and Exchange Commission, Publication, Missouri Baptist Medical Center, NYSE, BJC, Physician, Genesis, Disaster, Barnes-Jewish Hospital, Patient, Risk, Field line, Medical device, Medicine

With this equipment, BJC becomes the first hospital system in the midwest providing the latest robotic technology to treat cardiac arrhythmia, and Missouri Baptist Medical Center becomes the first hospital to successfully treat patients with the Genesis RMN system in the region.

Key Points: 
  • With this equipment, BJC becomes the first hospital system in the midwest providing the latest robotic technology to treat cardiac arrhythmia, and Missouri Baptist Medical Center becomes the first hospital to successfully treat patients with the Genesis RMN system in the region.
  • Robotic Magnetic Navigation introduces the benefits of robotic precision and safety to cardiac ablation, a common, minimally invasive procedure to treat arrhythmias.
  • The Genesis RMN system consists of two robotically controlled magnets, a flexible catheter with a magnetic tip, and an operating console.
  • Stereotaxis(NYSE: STXS) is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures.

Stereotaxis Reports 2021 Third Quarter Financial Results

Retrieved on: 
Thursday, November 11, 2021
Health, Safety, Adoption, Ecosystem, Pandemic, Marginal cost, Security (finance), Arrhythmia, CEO, Technology, International, Instagram, Forward-looking statement, Robotic magnetic navigation, YouTube, Twitter, Operating cost, Company, U.S. Securities and Exchange Commission, GLOBE, LinkedIn, MicroPort, NYSE, Physician, Disaster, Patient, Medical device, Video game, Pharmaceutical industry, Cryptocurrency

ST. LOUIS, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the third quarter ended September 30, 2021.

Key Points: 
  • ST. LOUIS, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the third quarter ended September 30, 2021.
  • We are confident in the transformative impact these innovations will have on patients, physicians, providers, and on Stereotaxis strategic and financial future.
  • Revenue for the third quarter of 2021 totaled $9.1 million, up 5% from $8.7 million in the prior year third quarter.
  • Negative free cash flow for the third quarter was ($1.5) million, compared to ($0.2) million in the prior year third quarter.

Stereotaxis Technology, Clinical Value and Innovations to be Highlighted at Society for Cardiac Robotic Navigation Meeting

Retrieved on: 
Monday, November 8, 2021
Health, Safety, Adoption, Robotics, Telerobotics, Pandemic, Arrhythmia, CEO, Technology, Society, Tachycardia, Growth, Instagram, Cardiology, Forward-looking statement, Robotic magnetic navigation, YouTube, Twitter, Company, GLOBE, LinkedIn, U.S. Securities and Exchange Commission, NYSE, Atrial fibrillation, Physician, Disaster, Medical device

SCRN was formed with the mission to advance clinical awareness, scientific research and technology innovation for robotic technologies in cardiology.

Key Points: 
  • SCRN was formed with the mission to advance clinical awareness, scientific research and technology innovation for robotic technologies in cardiology.
  • The SCRN meeting hosts cardiologists, fellows, innovators, industry leaders and scientists to debate, discuss, challenge, share, educate and learn with peers.
  • The hybrid in-person and virtual event includes several presentations on Stereotaxis technology, clinical value and innovations.
  • We are honored to join such a prestigious group of physicians and thought leaders at the Society for Cardiac Robotic Navigations annual meeting, said David Fischel, chairman and CEO of Stereotaxis.

Stereotaxis to Report Third Quarter 2021 Financial Results on November 11, 2021

Retrieved on: 
Thursday, October 28, 2021
Safety, Arrhythmia, Robotic magnetic navigation, LinkedIn, Twitter, NYSE, YouTube, International, Company, Instagram, Webcast, Health, GLOBE, Physician, Medical device

ST. LOUIS, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2021 third quarter on Thursday, November 11, 2021 before the open of the U.S. financial markets.

Key Points: 
  • ST. LOUIS, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2021 third quarter on Thursday, November 11, 2021 before the open of the U.S. financial markets.
  • The Company will host a conference call and webcast at 10 a.m. EST that day to discuss the Companys results and corporate developments.
  • To access the live call, dial 800-367-2403 (US and Canada) or 334-777-6978 (International) and give the participant pass code 1935969.
  • Stereotaxis (NYSE: STXS) is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures.